We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
  • SKIP TO CONTENT
  • SKIP NAVIGATION
  • Drug Products
    • Books
    • FDAnews Books Library
    • Events
    • Form 483s Database
    • Subscription Newsletters
    • Free Newsletters
    • Webinar Training Pass
    • eCFR and Guidances
  • Device Products
    • Books
    • FDAnews Books Library
    • Events
    • Form 483s Database
    • Subscription Newsletters
    • Free Newsletters
    • Webinar Training Pass
    • eCFR and Guidances
  • Clinical Products
  • Advertising
  • White Papers
  • Contact Us
  • About Us
  • COVID-19
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » FDA: NO CHANGE TO ACE-INHIBITOR WARNINGS, DESPITE NEW

FDA: NO CHANGE TO ACE-INHIBITOR WARNINGS, DESPITE NEW

June 8, 2006

The FDA will not change its warnings for pregnant women taking certain anti-hypertension medicines -- even though a study it cosponsored shows an elevated risk of birth defects in the first trimester.

The agency said during a conference call that it would not change its warnings for angiotensin-converting-enzyme (ACE) inhibitors because the FDA believes the study is not conclusive and existing black box warnings are sufficient to protect women's health. The study, Major Congenital Malformations after First-Trimester Exposure to ACE Inhibitors, published in The New England Journal of Medicine (NEJM), found a fetus faced 2.7 times the risk of birth defects when these inhibitors were used during the first three months of pregnancy.

NEJM recommends that the FDA warn women not to take these drugs during the first trimester. ACE inhibitors, which are used to lower blood pressure and to preserve kidney function in people with diabetes, are commonly prescribed drugs, with 42 million prescriptions written each year.

The agency said that its current black box warning that women should stop using these drugs as soon as possible when they become pregnant is sufficient to cover risks in the first trimester. The warning states that the drugs can cause injury and even death to the developing fetus when used during the second and third trimesters of pregnancy.

The FDA needs to further review the study and wants additional data before changing its warning, Sandra Kweder, deputy director of the Office of New Drugs, said. The study's findings are "considered preliminary data," she added.

However, the agency will notify the public about the study. The results are "important enough and impressive enough to tell people about," Robert Temple, associate director for medical policy, said. The FDA and HHS' Agency for Healthcare Research and Quality jointly funded the study.

The study represents the first extensive study of ACE inhibitors' use during the first trimester and illustrates a severe lack of information on such risks, NEJM said in an attached editorial. "This is not the last word on the subject, but it is shocking to realize that it is almost the first," the editorial said. (http://www.fdanews.com/did/5_112/)

KEYWORDS FDAnews Drug Daily Bulletin

Upcoming Events

  • 10Mar

    FDA Drug GMP Facility Inspections During the Pandemic

  • 16Mar

    Pharmaceutical Naming Regulation: Understanding the Latest Developments

  • 18Mar

    Pharmaceutical Postmarket Surveillance: Latest Developments in the Era of COVID-19

  • 23Mar

    Data Integrity for GCP Professionals: Core Requirements, Expectations and Challenges

  • 30Mar

    Data Integrity for GMP/Postmarket Professionals: Core Requirements, Expectations and Challenges

  • 06Apr

    Medical Device Cybersecurity: Understand the Latest Developments

Featured Products

  • Biological Risk Evaluation and Management for Medical Devices

  • GMP Inspection Preparation Checklist: A Tool for Internal Auditing

Featured Stories

  • Effective text

    Pfizer/BioNTech Vaccine Equally Effective for All Age Groups, Israeli Study Says

  • Siemens Healthineers logo

    Siemens Healthineers’ COVID-19 Antigen Lab Test Receives CE Mark

  • UKflag.jpg

    UK Study Says Single Shot of Pfizer/BioNTech Vaccine Significantly Lessened Asymptomatic Infections

  • emergency use authorization approved

    Eurofins Receives FDA Emergency Authorization for Over-the-Counter COVID-19 Test

The Revised ICH E8: A Guide to New Clinical Trial Requirements

Learn More
  • Drug Products
    • Quality
    • Regulatory Affairs
    • GMPs
    • Inspections and Audits
    • Postmarket Safety
    • Submissions and Approvals
    • Research and Development
    • Commercial Operations
  • Device Products
    • Quality
    • Regulatory Affairs
    • QSR
    • Inspections and Audits
    • Postmarket Safety
    • Submissions and Approvals
    • Research and Development
    • Commercial Operations
  • Clinical Products
    • Trial Design
    • Data Integrity
    • GCP
    • Inspections and Audits
    • Transparency
  • Privacy Policy
  • Do Not Sell My Personal Information
Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 703.538.7600 – Fax 703.538.7676 – Toll free 888.838.5578

Copyright © 2021. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing